|
US4082845A
(en)
|
1977-04-25 |
1978-04-04 |
Merck & Co., Inc. |
3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines
|
|
JPS5665863U
(enExample)
|
1979-10-25 |
1981-06-02 |
|
|
|
JPS5665863A
(en)
|
1979-10-31 |
1981-06-03 |
Tokyo Organ Chem Ind Ltd |
Novel aniline derivative, its preparation and pesticide containing the same
|
|
JPS625888Y2
(enExample)
|
1980-08-14 |
1987-02-10 |
|
|
|
JPS5738777A
(en)
|
1980-08-19 |
1982-03-03 |
Sogo Yatsukou Kk |
2-sufanilamidopyrathyn derivative
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
US5643755A
(en)
|
1994-10-07 |
1997-07-01 |
Regeneron Pharmaceuticals Inc. |
Nucleic acid encoding tie-2 ligand
|
|
US5879672A
(en)
|
1994-10-07 |
1999-03-09 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 ligand 1
|
|
AU701568B2
(en)
|
1994-09-22 |
1999-02-04 |
Licentia Ltd |
Promoter for the receptor tyrosine kinase, tie
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
ZA971896B
(en)
|
1996-03-26 |
1998-09-07 |
Du Pont Merck Pharma |
Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
|
|
EP0929526B1
(en)
|
1996-09-25 |
2005-07-27 |
AstraZeneca AB |
Qinoline derivatives inhibiting the effect of growth factors such as vegf
|
|
US6030831A
(en)
|
1997-09-19 |
2000-02-29 |
Genetech, Inc. |
Tie ligand homologues
|
|
US6093728A
(en)
|
1997-09-26 |
2000-07-25 |
Asta Medica Aktiengesellschaft |
Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
|
|
GB9721437D0
(en)
|
1997-10-10 |
1997-12-10 |
Glaxo Group Ltd |
Heteroaromatic compounds and their use in medicine
|
|
AU776788C
(en)
|
1998-12-16 |
2005-10-27 |
Warner-Lambert Company |
Treatment of arthritis with MEK inhibitors
|
|
EP1140062B1
(en)
|
1999-01-07 |
2005-04-06 |
Warner-Lambert Company LLC |
Treatment of asthma with mek inhibitors
|
|
WO2000045435A1
(en)
|
1999-01-29 |
2000-08-03 |
The University Of Akron |
Polyimides used as microelectronic coatings
|
|
IL147619A0
(en)
|
1999-07-16 |
2002-08-14 |
Warner Lambert Co |
Method for treating chronic pain using mek inhibitors
|
|
GB2356398A
(en)
|
1999-11-18 |
2001-05-23 |
Lilly Dev Ct S A |
Preparation of arylsulfamides
|
|
DE60021423T2
(de)
|
1999-12-21 |
2006-04-13 |
Sugen, Inc., San Diego |
4-substituierte 7-aza-indolin-2-one und ihre verwendung als proteinkinaseinhibitoren
|
|
US6492529B1
(en)
|
2000-01-18 |
2002-12-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Bis pyrazole-1H-pyrazole intermediates and their synthesis
|
|
US7238813B2
(en)
|
2000-11-29 |
2007-07-03 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
KR20020096367A
(ko)
|
2001-06-19 |
2002-12-31 |
주식회사 티지 바이오텍 |
관절염 예방 또는 치료제 및 그것의 스크리닝 방법
|
|
ES2284887T3
(es)
*
|
2001-07-11 |
2007-11-16 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Metodos para tratar enfermedades transmitidas por citocinas.
|
|
BRPI0214840B8
(pt)
|
2001-12-21 |
2021-05-25 |
The Wellcome Trust |
métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa
|
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
PE20040522A1
(es)
*
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
EP1534268A4
(en)
|
2002-08-09 |
2006-11-02 |
Merck & Co Inc |
TYROSINE KINASE INHIBITORS
|
|
US20060141472A1
(en)
|
2003-03-20 |
2006-06-29 |
Miikka Vikkula |
Medical use of ras antagonists for the treatment of capillary malformation
|
|
ATE454152T1
(de)
|
2003-06-13 |
2010-01-15 |
Novartis Pharma Gmbh |
2-aminopyrimidin-derivate als raf-kinase-hemmer
|
|
TW200538120A
(en)
|
2004-02-20 |
2005-12-01 |
Kirin Brewery |
Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
|
|
TW200616974A
(en)
|
2004-07-01 |
2006-06-01 |
Astrazeneca Ab |
Chemical compounds
|
|
CN101048388A
(zh)
|
2004-08-31 |
2007-10-03 |
阿斯利康(瑞典)有限公司 |
喹唑啉酮衍生物及其作为B－Raf抑制剂的用途
|
|
CA2583096A1
(en)
|
2004-10-15 |
2006-04-20 |
Astrazeneca Ab |
Quinoxalines as b raf inhibitors
|
|
GB0423554D0
(en)
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
|
GB0428082D0
(en)
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
|
EP2942349A1
(en)
|
2004-12-23 |
2015-11-11 |
Deciphera Pharmaceuticals, LLC |
Enzyme modulators and treatments
|
|
EP1960394A2
(en)
|
2005-11-15 |
2008-08-27 |
Bayer HealthCare AG |
Pyrazolyl urea derivatives useful in the treatment of cancer
|
|
JP2009518298A
(ja)
*
|
2005-12-01 |
2009-05-07 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌治療に有用な尿素化合物
|
|
CN101365682A
(zh)
|
2005-12-08 |
2009-02-11 |
千禧药品公司 |
具有激酶抑制活性的双环化合物
|
|
US7989461B2
(en)
|
2005-12-23 |
2011-08-02 |
Amgen Inc. |
Substituted quinazolinamine compounds for the treatment of cancer
|
|
US7951819B2
(en)
|
2006-04-26 |
2011-05-31 |
Cancer Research Technology Limited |
Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
|
EP1992628A1
(en)
|
2007-05-18 |
2008-11-19 |
Glaxo Group Limited |
Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
|
|
WO2008044688A1
(en)
|
2006-10-11 |
2008-04-17 |
Daiichi Sankyo Company, Limited |
Urea derivative
|
|
US7790756B2
(en)
*
|
2006-10-11 |
2010-09-07 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
|
EP2167692B1
(en)
|
2007-07-10 |
2013-05-22 |
Neurim Pharmaceuticals (1991) Ltd. |
Cd44 splice variants in neurodegenerative diseases
|
|
AU2008337286B2
(en)
|
2007-12-19 |
2014-08-07 |
Cancer Research Technology Limited |
Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
|
|
GB0807609D0
(en)
|
2008-04-25 |
2008-06-04 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
BRPI0920707A2
(pt)
|
2008-10-02 |
2015-12-29 |
Respivert Ltd |
compostos
|
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
|
US8299074B2
(en)
|
2008-12-11 |
2012-10-30 |
Respivert Ltd. |
P38 MAP kinase inhibitors
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
EP2470898A4
(en)
|
2009-08-24 |
2013-03-13 |
Genentech Inc |
DETERMINATION OF THE SENSITIVITY OF CELLS FOR B-RAF HEMMER TREATMENT BY DETECTION OF KRAS MUTATIONS AND RTK EXPRESSION MIRRORS
|
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
|
US8815896B2
(en)
*
|
2010-02-01 |
2014-08-26 |
The Institute Of Cancer Research: Royal Cancer Hospital |
1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
|
|
GB201005589D0
(en)
|
2010-04-01 |
2010-05-19 |
Respivert Ltd |
Novel compounds
|
|
US9260410B2
(en)
|
2010-04-08 |
2016-02-16 |
Respivert Ltd. |
P38 MAP kinase inhibitors
|
|
US9024041B2
(en)
|
2010-04-08 |
2015-05-05 |
Respivert Ltd. |
P38 MAP kinase inhibitors
|
|
GB201010196D0
(en)
|
2010-06-17 |
2010-07-21 |
Respivert Ltd |
Methods
|
|
US8933228B2
(en)
|
2010-06-17 |
2015-01-13 |
Respivert, Ltd. |
Respiratory formulations and compounds for use therein
|
|
GB201010193D0
(en)
|
2010-06-17 |
2010-07-21 |
Respivert Ltd |
Medicinal use
|
|
WO2012008564A1
(ja)
|
2010-07-16 |
2012-01-19 |
協和発酵キリン株式会社 |
含窒素芳香族複素環誘導体
|
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
|
EP2701694A4
(en)
|
2011-04-28 |
2014-10-08 |
Univ Duke |
METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
|
|
AU2012273007A1
(en)
|
2011-06-23 |
2014-01-30 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyme inhibitor compounds
|
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
|
SG2014005029A
(en)
|
2011-09-01 |
2014-03-28 |
Novartis Ag |
Use of organic compound for the treatment of noonan syndrome
|
|
PT2763984T
(pt)
|
2011-10-03 |
2016-07-25 |
Respivert Ltd |
1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureias como inibidores da map cinase p38
|
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
|
WO2014033446A1
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
|
WO2014033447A2
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
|
US9783556B2
(en)
|
2012-08-29 |
2017-10-10 |
Respivert Limited |
Kinase inhibitors
|
|
EP2925742B1
(en)
|
2012-11-16 |
2016-10-26 |
Respivert Limited |
Kinase inhibitors
|
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
|
TW201522341A
(zh)
|
2013-03-15 |
2015-06-16 |
Respivert Ltd |
化合物
|
|
EA027782B1
(ru)
|
2013-04-02 |
2017-08-31 |
Респайверт Лимитед |
Ингибитор киназ
|
|
EP2981534B1
(en)
|
2013-04-02 |
2017-07-19 |
Topivert Pharma Limited |
Kinase inhibitors based upon n-alkyl pyrazoles
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
CN106029651A
(zh)
|
2013-12-20 |
2016-10-12 |
瑞斯比维特有限公司 |
用作激酶抑制剂的脲衍生物
|
|
JP6586098B2
(ja)
|
2014-02-14 |
2019-10-02 |
レスピバート・リミテツド |
キナーゼ阻害剤としてのピラゾリル尿素
|
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
|
WO2016051186A1
(en)
|
2014-10-01 |
2016-04-07 |
Respivert Limited |
N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
|